Brief introduction of Lei Pharmaceutical Group Co., Ltd.:

Lei Pharmaceutical Group, one of the four largest pharmacies in China, was established on March 3, 20041,1994, and was one of the first owners of Chinese time-honored brands, national top-secret projects and national intangible cultural heritage. The legal representative is Zhang Bangguo, and the business scope of the company includes: production and sales of Chinese and western medicines, Chinese herbal medicines, Chinese herbal pieces and medical consumables; Warehousing and freight services; Wholesale and retail: health food (health wine, health tea, health drink); Wholesale and retail: non-hazardous chemicals, cosmetics, etc.

In recent years, Lei Yunshang has gradually developed into a large health group enterprise integrating industry, commerce, chain, medicine and health care. It has a health management system of prophase prevention, metaphase treatment and back-end rehabilitation treatment. It owns six industrial enterprises including Suzhou Leiyunshang, Changshu Leiyunshang and Guangdong Leiyunshang.

In the respiratory field, the team of Academician Zhong Nanshan from the First Affiliated Hospital of Guangzhou Medical University, the State Key Laboratory of Respiratory Diseases and Guangzhou Customs Technology Center conducted in vitro pharmaceutical research on anti-COVID-19 virus in P3 laboratory. This study initially found that Liushen capsule/pill and other Chinese patent medicines can inhibit the cytopathic effect caused by COVID-19 in vitro.